Roche's Tecentriq cocktail notches another lung cancer success
ZURICH (Reuters) - Roche's immunotherapy Tecentriq combined with other drugs boosted lung cancer patients' survival versus an older cocktail, the Swiss company's latest trial success as it seeks an edge on Merck and Bristol-Myers Squibb.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cancer | Cancer & Oncology | Health | Immunotherapy | Lung Cancer | Merck | Switzerland Health